IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i2d10.1007_s40264-017-0605-3.html
   My bibliography  Save this article

Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study

Author

Listed:
  • Prashant V. Nigwekar

    (Pravara Institute of Medical Sciences)

  • Anuj Kumar

    (Pravara Institute of Medical Sciences)

  • Vikram V. Padbidri

    (Jehangir Hospital)

  • Amlan Choudhury

    (KPC Medical College)

  • Amol B. Chaudhari

    (Serum Institute of India Pvt. Ltd)

  • Prasad S. Kulkarni

    (Serum Institute of India Pvt. Ltd)

Abstract

Introduction and Aim A trivalent live attenuated influenza vaccine (Nasovac-S®) was developed and licensed in India. A phase 4 study was conducted to assess safety. Methodology This non-randomized, open-label, single-arm study among individuals ≥ 2 years of age involved administration of 0.5 mL of Nasovac-S intranasally, with a 1-month follow-up after vaccination. Adverse events (AEs) were collected via structured diaries. Results Among 500 vaccinated subjects, 160 were between 2 and 17 years of age, 240 were 18–49 years old and 100 were 50 years and older. A total of 533 solicited reactions were reported. The majority of these reactions were mild, and almost all of them resolved without any sequelae. A total of 20% of subjects reported at least one local solicited reaction, and 23% reported at least one systemic solicited reaction. None of the 45 unsolicited AEs reported by 37 subjects (7.4%) were causally related to the study vaccine. Conclusions The data from the study adds to the existing safety database of Nasovac-S. Registry Clinical Trials Registry of India (CTRI/2015/08/006074).

Suggested Citation

  • Prashant V. Nigwekar & Anuj Kumar & Vikram V. Padbidri & Amlan Choudhury & Amol B. Chaudhari & Prasad S. Kulkarni, 2018. "Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study," Drug Safety, Springer, vol. 41(2), pages 171-177, February.
    • Handle: RePEc:spr:drugsa:v:41:y:2018:i:2:d:10.1007_s40264-017-0605-3
    DOI: 10.1007/s40264-017-0605-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-017-0605-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-017-0605-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:2:d:10.1007_s40264-017-0605-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.